Will Intravenous Inron reduce blood transfusion in patients undergoing treatment for ovarian cancer

Clinical experience with intravenous iron in anaemic patient receiving cancer treatment for epithelial ovarian carcinomas

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/05/019378

Enrollment

Registered

2019-05-27

Start date

Unknown

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C569- Malignant neoplasm of unspecifiedovary

Interventions

Intervention1: ferric carboxy maltose: Dose 500 mg Route Intravenous after after diluting in 500 ml Normal saline Frequency - Once . At the detection of anaemia Control Intervention1: Oral Iron: Dose

Eligibility

Inclusion criteria

Inclusion criteria: age 18–75 years with normal liver and kidney function, no prior radiotherapy and an Eastern Cooperative Oncology Group (ECOG) performance status of =2 -Patient with epithelial ovarian cancer receiving Neoadjuvant or adjuvant chemotherapy or planned for surgery , having Hemoglobin level =10 gm/dL

Exclusion criteria

Exclusion criteria: Erythropoitin Stimulating Agent administration during chemotherapy course -Allergic reaction to ferric carboxymaltose - Serum ferritin >800 ng/mL OR serum trasferrin saturation >50%

Design outcomes

Primary

Measure	Time frame
Reduction in Blood transfusion Improvement in haemoglobinTimepoint: At three months Completion of chemotherapy	—

Secondary

Measure	Time frame
Improvemnet in Serum ferritin, Serum Iron levels and Total Iron Binding capacityTimepoint: 3 months, 6 months	—

Countries

India

Contacts

Public ContactAnupama R

Amrita Institute of Medical Sciences

anupamashyam@gmail.com8891728600

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026